Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a $50.00 target price on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Stephens initiated coverage on shares of Actinium Pharmaceuticals […]

Related Keywords

,Vanguard Group Inc ,Sanders Morris Harris ,Institutional Investors Weigh In On Actinium Pharmaceuticals ,Actinium Pharmaceuticals Company Profile ,News Ratings For Actinium Pharmaceuticals Daily ,Cantor Fitzgerald ,Actinium Pharmaceuticals ,Creative Financial Designs Inc ,Virtu Financial ,Analyst Recommendations For Actinium Pharmaceuticals ,Actinium Pharmaceuticals Price Performance ,Brandywine Global Investment Management ,Maxim Group ,Actinium Pharmaceuticals Inc ,Free Report ,Moderate Buy ,Get Free Report ,Morris Harris ,Financial Designs ,Actinium Pharmaceuticals Daily ,